Evidence map›Paper›PMID 42920036›Full record

ArticleRheumatology and therapy2026

Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study.

Jieruo Gu, Liangjing Lu, Qiang Wang, Xiaobing Wang, Yongjing Cheng, Shengqian Xu, Yi Zhao, Qi Zhu, Xenofon Baraliakos, Matthew A Brown and 6 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03928704 (A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03928704 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

TypeinterventionalSponsorUCB Biopharma SRLRan2019 to 2023Enrolled274ConditionsNonradiographic Axial SpondyloarthritisArmsBimekizumab, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jieruo GuDepartment of Rheumatology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Liangjing LuSchool of Medicine, Renji Hospital, Jiaotong University, Shanghai, China.
Qiang WangDepartment of Rheumatology, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Xiaobing WangRheumatology Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yongjing ChengNational Center for Clinical Laboratories, Beijing Hospital, Dongdan, Beijing, China.
Shengqian XuDepartment of Rheumatism and Immunity, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China.
Yi ZhaoDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qi ZhuDepartment of Rheumatology, Shanghai Guanghua Integrated Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Xenofon BaraliakosRheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany.
Matthew A BrownGenomics England, London, UK.
Atul DeodharDivision of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.
James Cheng-Chung WeiInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Alexander MartenUCB, Monheim am Rhein, Germany.
Marga OortgiesenUCB, Raleigh, NC, USA.
Tom VauxUCB, Slough, UK.
Huji XuDepartment of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Naval Medical University, Shanghai, China. huji_xu@tsinghua.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBimekizumab, a humanised monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, was efficacious and well tolerated to 52 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in the global phase 3 multicentre study BE MOBILE 1. In this pre-specified analysis, we examine in more detail the efficacy and safety of bimekizumab in the Chinese subpopulation of patients with nr-axSpA from BE MOBILE 1.

methodsBE MOBILE 1 comprised a 16-week double-blind, placebo-controlled period and 36-week maintenance period. Patients with nr-axSpA were randomised to receive subcutaneous bimekizumab 160 mg every 4 weeks or placebo to week 16; thereafter, all patients received bimekizumab. Here we report efficacy and safety outcomes to week 52 for the Chinese subpopulation. No formal statistical comparisons were made; results should be interpreted as nominal.

resultsOverall, 36/274 patients in BE MOBILE 1 were enrolled in China (bimekizumab-randomised 18; placebo-randomised 18); 32 completed week 52. A greater proportion of bimekizumab- vs placebo-randomised patients achieved Assessment of SpondyloArthritis international Society (ASAS) ≥ 40% response (38.9% vs 22.2%), ASAS partial remission (33.3% vs 11.1%), and Axial Spondyloarthritis Disease Activity Score < 2.1 (77.7% vs 49.7%) at week 16. By week 52, improvements were comparable between bimekizumab-randomised and placebo-randomised patients who had switched to bimekizumab. Similar trends were observed for objective signs of inflammation, spinal pain, physical function, health-related quality of life, and peripheral manifestations. To week 52, treatment-emergent adverse events (TEAEs) occurred in 33 bimekizumab-treated patients (91.7%), with upper respiratory tract infection the most frequent (10 patients [27.8%]). Four patients (11.1%) had serious TEAEs; four had fungal infections (11.1%; all Tinea). No patients experienced adjudicated inflammatory bowel disease or uveitis.

conclusionsIn patients with nr-axSpA from China, bimekizumab showed rapid and sustained efficacy improvements to week 52 and was well tolerated, consistent with the global patient population. Graphical Abstract is available for this article.

trial registrationClinicalTrials.gov identifier, NCT03928704.

Indexed as

Autoimmune diseasesAxial spondyloarthritisBiological therapyChinaCytokinesInflammation

Identifiers

PMID42920036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.